MRCT and Pharmidex form drug discovery collaboration

Published: 15-Apr-2010
Research & Development

Pharmidex will provide all in vivo ADME/PK drug discovery support to MRCT in 2010


Medical Research Council Technology (MRCT), based in London, UK, has chosen Pharmidex as its supplier of pharmacokinetic and ADME studies.

The partnership will give MRCT access to high quality laboratory services and expertise that will enable it to develop efficient, high quality studies.

Pharmidex provides ADME/PK, drug safety and bioanalytical services for lead optimisation and drug development activities.

The company also has a CNS solutions platform including NeuroPK and NeuroPD for direct assessment of drug levels and biochemical responses in any brain region.

  • Companies:
  • Pharmidex
  • Medical Research Council Technology
See more

You may also like

Research & Development

Pharmidex moves onto the Stevenage Bioscience Catalyst campus

Read more
Modern facilities encourage dialogue and interaction between companies and researchers on the site

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
  4. Neurolentech partners with Kaerus Bioscience to advance neurodevelopmental disorder research Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes
  5. Amarna Therapeutics appoints Aurelia Caparrós as new Chief Business Officer Aurellia will be reponsible for driving Amarna's growth in the Netherlands and Spain

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Research & Development

Pharmidex moves onto the Stevenage Bioscience Catalyst campus

Modern facilities encourage dialogue and interaction between companies and researchers on the site
Research & Development

Domainex and Pharmidex form drug discovery services alliance

Contract research company Domainex, based in Cambridge, UK and Pharmidex have agreed to combine their expertise and innovative technologies to provide the market with an integrated, high-quality drug discovery services platform.
Sustainability

MRCT signs agreement to develop immunotherapy for respiratory disease

<p>The UK-based Medical Research Council (MRC) and MRC Technology (MRCT) in the UK have signed exclusive agreements with Centocor in the US, now known as Centocor Ortho Biotech, for the development of a novel immunotherapy targeting respiratory disease.</p>
Research & Development

Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool

The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Research & Development

New automated tissue dissociation systems

Introducing the new Singulator series (100 and 200)
Manufacturing

Memel Biotech and Therabest collaborate to develop exosome-based cell therapies

The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Research & Development

Fasenra for EGPA: addressing unmet needs

Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Subscribe now